↓ Skip to main content

Dove Medical Press

Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease

Overview of attention for article published in Neuropsychiatric Disease and Treatment, October 2017
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
40 Mendeley
Title
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
Published in
Neuropsychiatric Disease and Treatment, October 2017
DOI 10.2147/ndt.s145916
Pubmed ID
Authors

Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono

Abstract

Effects of dopaminergic medication on executive function in patients with Parkinson's disease (PD) are inconsistent. We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4-7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson's Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient's background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Effects of dopaminergic drug adjustment on executive function differ according to the patient's clinical stage and depend on LED in de novo stage.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Other 6 15%
Student > Ph. D. Student 6 15%
Student > Master 4 10%
Student > Bachelor 3 8%
Student > Doctoral Student 3 8%
Other 2 5%
Unknown 16 40%
Readers by discipline Count As %
Psychology 8 20%
Neuroscience 4 10%
Nursing and Health Professions 3 8%
Medicine and Dentistry 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Other 2 5%
Unknown 18 45%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,583
of 3,131 outputs
Outputs of similar age
#291,092
of 331,218 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#50
of 64 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,218 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.